Dong-A, Astellas Korea cooperate over co-promotion of Irribow

Dong-A Pharmaceutical has joined hands with Astellas Pharma Korea to make a joint marketing of Irribow (ramosetron), serotonin 5-HT3 receptor antagonist which is indicated for diarrhea-predominant irritable bowel syndrome in male.

To this end, both firms signed a co-promotion agreement on September 17.

Irribow improves abnormal bowel movement associated with the acceleration of intestinal...